Citations

Showing 10 of 108104 citations.

Spontaneous intracranial hypotension
Wald, John T. , Diehn, Felix E.

Mayo Clinic

Applied Radiology | April 4, 2022 | Volume: No volume available | Issue: No issue available | Pages: 18-22

10.37549/ar2510 Get It

A radiolucent esophageal foreign body: Diagnosis, management, and potential complications
Plowman, R. Scooter, Dance, Logan, Jorgensen, Scott A., Towbin, Richard B. , Barnes, Craig, Towbin, Alexander J.

Mayo Clinic

Applied Radiology | April 4, 2022 | Volume: No volume available | Issue: No issue available | Pages: 28-29

10.37549/ar2474 Get It

Pierre Robin sequence
Jorgensen, Scott A., Towbin, Richard B. , Sugi, Mark , Towbin, Alexander J.

Mayo Clinic

Applied Radiology | April 4, 2022 | Volume: No volume available | Issue: No issue available | Pages: 36-37

10.37549/ar2374 Get It

Navigating contrast-enhanced digital mammography
Lewis, Tiffany C., Pizzitola, Victor J. , Patel, Bhavika

Mayo Clinic

Applied Radiology | April 4, 2022 | Volume: No volume available | Issue: No issue available | Pages: 21-28

10.37549/ar2363 Get It

Percutaneous vertebroplasty: Overview, clinical applications, and current state
McDonald, Robert J. , Lane, John I. , Wald, John T. , Diehn, Felix E.

Mayo Clinic

Applied Radiology | April 4, 2022 | Volume: No volume available | Issue: No issue available | Pages: 24-30

10.37549/ar2346 Get It

Medial and Lateral Posterior Tibial Slope in the Skeletally Immature: A Cadaveric Study
Anchustegui, Nicolas G., Grimm, Nathan L. , Milbrandt, Todd A. , Rustad, Audrey , Shea, Cooper, Troyer, Stockton , Dingel, Aleksei , Ganley, Theodore J. , Shea, Kevin G. , Fabricant, Peter D

Mayo Clinic

Orthopaedic Journal of Sports Medicine | April 4, 2022 | Volume: 10 | Issue: 4 | Pages: No page available

10.1177/23259671221088331 | PMID 35400135 Get It

Background: An increased posterior tibial slope (PTS) results in greater force on the anterior cruciate ligament (ACL) and is a risk factor for ACL injuries. Biomechanical studies have suggested that a reduction in the PTS angle may lower the risk of ACL injuries. However, the majority of these investigations have been in the adult population. Purpose: To assess the mean medial and lateral PTS on pediatric cadaveric specimens without known knee injuries. Study Design: Cross-sectional study; Level of evidence, 3. Methods: A total of 39 pediatric knee specimens with computed tomography scans were analyzed. Specimens analyzed were between the ages of 2 and 12 years. The PTS of each specimen was measured on sagittal computed tomography slices at 2 locations for the medial and lateral angles. The measurements were plotted graphically by age to account for the variability in development within age groups. The anterior medial and lateral tibial plateau widths were measured. The distance between the top of the tibial plateau and the physis was measured. The independent-samples t test and analysis of variance were used to analyze the measurements. Results: The mean PTS angle for the medial and lateral tibial plateaus was 5.53° ± 4.17° and 5.95° ± 3.96°, respectively. The difference between the PTS angles of the medial and lateral tibial plateaus was not statistically significant ( P > .05). When plotted graphically by age, no trend between age and PTS was identified. Conclusion: This data set offers values for the PTS in skeletally immature specimens without a history of ACL injury and suggests that age may not be an accurate predictive factor for PTS.
Imaging of esophageal emergencies
Currie, S., Menias, Christine O. , Mellnick, Vincent M.

Mayo Clinic

Applied Radiology | April 4, 2022 | Volume: No volume available | Issue: No issue available | Pages: 16-22

10.37549/ar2313 Get It

Ectopic ureteral insertion into the seminal vesicle associated with ipsilateral renal dysplasia
Aouad, Pascale , Serhal, Ali , Mehanna, Asaad M., Menias, Christine O.

Mayo Clinic

Applied Radiology | April 4, 2022 | Volume: No volume available | Issue: No issue available | Pages: 46-47

10.37549/ar2305 Get It

Phase I/randomized phase II trial of TRC105 plus bevacizumab versus bevacizumab in recurrent glioblastoma: North Central Cancer Treatment Group N1174 (Alliance)
Galanis, Evanthia , Anderson, S. Keith , Twohy, Erin , Butowski, Nicholas , Hormigo, Adı́lia , Schiff, David , Jaeckle, Kurt A. , Kumar, Shaji , Kaufmann, Timothy J. , Geyer, Susan M. , Kumthekar, Priya , Campian, Jian , Buckner, Jan C. , Wen, Patrick Y , Kaufmann, Timothy J , Giannini, Caterina , Buckner, Jan C , Galanis, Evanthia , Anderson, S Keith , Omuro, Antonio , Giannini, Caterina

Mayo Clinic

Neuro-Oncology Advances | April 4, 2022 | Volume: 4 | Issue: 1 | Pages: No page available

10.1093/noajnl/vdac041 | PMID 35664553 Get It

Abstract Background Patients with glioblastoma (GBM) have a poor prognosis and limited effective treatment options. Bevacizumab has been approved for treatment of recurrent GBM, but there is questionable survival benefit. Based on preclinical and early clinical data indicating that CD105 upregulation may represent a mechanism of resistance to bevacizumab, we hypothesized that combining bevacizumab with the anti-CD105 antibody TRC105 may improve efficacy in recurrent GBM. Methods Phase I dose-escalation/comparative randomized phase II trial in patients with GBM. During phase I, the maximum tolerated dose (MTD) of TRC105 in combination with bevacizumab was determined. In phase II, patients were randomized 1:1 to TRC105 and bevacizumab or bevacizumab monotherapy. Patients received TRC105 (10 mg/kg) weekly and bevacizumab (10 mg/kg) every 2 weeks. Efficacy, as assessed by progression-free survival (PFS), was the primary endpoint; safety, quality of life, and correlative outcomes were also evaluated. Results In total, 15 patients were enrolled in phase I and 101 in phase II; 52 patients were randomized to TRC105 with bevacizumab and 49 to bevacizumab monotherapy. The MTD was determined to be 10 mg/kg TRC105 weekly plus bevacizumab 10 mg/kg every 2 weeks. An increased occurrence of grade ≥3 adverse events was seen in the combination arm, including higher incidences of anemia. Median PFS was similar in both treatment arms: 2.9 months for combination versus 3.2 months for bevacizumab monotherapy (HR = 1.16, 95% CI = 0.75–1.78, P = .51). Quality of life scores were similar for both treatment arms. Conclusions TRC105 in combination with bevacizumab was well tolerated in patients with recurrent GBM, but no difference in efficacy was observed compared to bevacizumab monotherapy.
Presenting Symptoms in Patients Undergoing Coronary Artery Disease Evaluation: Association With Noninvasive Test Results and Clinical Outcomes in the PROMISE Trial
Lowenstern, Angela , Alexander, Karen P. , Pagidipati, Neha J. , Hill, C. Larry , Pellikka, Patricia A. , Cooper, Lawton S. , Hoffmann, Udo , Mark, Daniel B. , Douglas, Pamela S. , Mark, Daniel B , Douglas, Pamela S , Pellikka, Patricia A , Cooper, Lawton S , Alexander, Karen P , Alhanti, Brooke

Mayo Clinic

Circulation: Cardiovascular Quality and Outcomes | April 4, 2022 | Volume: 15 | Issue: 5 | Pages: No page available

10.1161/circoutcomes.121.008298 | PMID 35369715 Get It

Background: Patients evaluated for coronary artery disease have a range of symptoms and underlying risk. The relationships between patient-described symptoms, clinician conclusions, and subsequent clinical management and outcomes remain incompletely described. Methods: In this secondary analysis, we examined the association between 4 types of presenting symptoms (substernal/left-sided chest pain, other chest/neck/arm pain, dyspnea, and other symptoms) and patient risk, noninvasive test results, clinical management, and outcomes for stable outpatients randomized in the PROMISE (Prospective Multicenter Imaging Study for Evaluation of Chest Pain) trial. Multivariable regression models were used to evaluate differences in noninvasive test result, all-cause death/myocardial infarction/unstable angina hospitalization and cardiovascular death/myocardial infarction by symptom type. Results: Among 9996 patients, most presented with chest pain (47.2% substernal, 29.2% other), followed by dyspnea (14.9%), and other symptoms (8.7%). Patients with dyspnea were older (median age 63 versus 60, P ≤0.02) with higher baseline risk (78.2% with atherosclerotic cardiovascular disease >7.5% versus 67.6%, P ≤0.02). Using patients with substernal chest pain as a reference, there was no difference in noninvasive test positivity across symptom groups (all P >0.05), but test-positive patients with dyspnea (adjusted odds ratio, 0.66 [95% CI, 0.51–0.85]) or other symptoms (adjusted odds ratio, 0.65 [95% CI, 0.47–0.90]) were less likely to be referred for cardiac catheterization. While symptom type alone was not associated with outcomes, symptom presentation with chest pain or dyspnea did modify the association between a positive noninvasive test and clinical outcome (interaction P =0.025 for both all-cause death/myocardial infarction/unstable angina hospitalization and cardiovascular death/MI). Conclusions: Among low-risk outpatients evaluated for coronary artery disease, typicality of symptoms was not closely associated with higher baseline risk but was related to differences in processes of care and the prognostic value of a positive test. Adverse events were not associated with clinician risk estimates or symptoms alone. These unexpected findings highlight the limitation of relying solely on symptom presentation or clinician risk estimation to evaluate patients for suspected coronary artery disease. Registration: URL: https://www.clinicaltrials.gov ; Unique identifier: NCT01174550.